[SINGAPORE] Specialised Therapeutics Asia announced on April 5 that the initiation of an early access program for neratinib, an extended adjuvant treatment for early-stage HER2-positive (HER2+) breast cancer.
According to PR Newswire, Under this Special Access Program (SAP) select patients in Australia will be provided access to the medicine, where appropriate and when permitted by relevant regulatory authorities.
The SAP protocol allows for neratinib to be available to patients with HER2 overexpressing cancers.
In all cases, the patient must have a special clinical need that cannot be met by currently approved and available medicines.
Specialised Therapeutics' neratinib Special Access Program follows the signing of a key license agreement with Puma Biotechnology Inc. in November 2017, providing exclusive rights to commercialise neratinib in Australia, New Zealand and in South East Asia.
